Sirtuin substrate comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory measurement of NAD+ often begins with rapid quenching of cell or tissue samples to prevent enzymatic conversion. Acidic or alkaline extraction can precipitate proteins, but the chosen method affects recovery of oxidized and reduced forms. Enzymatic cycling assays provide high sensitivity by amplifying a NAD+-dependent reaction. High-performance liquid chromatography and mass spectrometry offer separation and structural confirmation. Each method has trade-offs in throughput, specificity, and the ability to distinguish NAD+ from close analogues.
Purified NAD+ is typically supplied as a white to off-white powder and stored desiccated at low temperature. Airtight containers limit moisture uptake, while protection from light reduces degradation of the nicotinamide ring. Aqueous stock solutions are less stable than solid material and are often aliquoted before freezing. Repeated freeze-thaw cycles can lower integrity, so working portions are kept separate. Purity is commonly checked by ultraviolet absorbance near 260 nm, high-performance liquid chromatography, or mass spectrometry.
NAD+ is relatively unstable in aqueous solution, especially at neutral or alkaline pH and at elevated temperatures. It is typically stored dry, protected from light and moisture, and kept cold or frozen for long-term use. Solutions are often prepared fresh or buffered to mildly acidic pH to slow hydrolysis. Repeated freeze-thaw cycles can reduce integrity. Laboratories may verify concentration using ultraviolet absorbance at 259 nm or by enzymatic assay. These handling practices are general laboratory conventions rather than universal rules.
Research on NAD+ often examines changes with age, diet, exercise, and disease states, but causal relationships are difficult to establish. Some studies measure NAD+ levels, while others assess enzyme activity or downstream markers. In the literature, terms such as "NAD+ decline" and "NAD+ boosting" appear in both scientific and commercial contexts, sometimes without precise definitions. Whether changes in measured NAD+ directly produce health effects remains an open question. Results from cells, animals, and humans cannot be assumed to translate directly.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized or precipitated solid |
| Solubility | Water-soluble | Also soluble in aqueous buffers; limited in nonpolar solvents |
| Typical storage | -20 °C, desiccated | Short-term solutions may be kept at 2-8 °C |
| Common analytical method | HPLC with UV detection | LC-MS provides additional confirmation |
| Stability risk | Hydrolysis | Accelerated by heat, extreme pH, and repeated freeze-thaw |
Nicotinamide adenine dinucleotide, abbreviated NAD+, is a dinucleotide composed of two nucleotides joined by phosphate groups. One nucleotide contains adenine; the other contains nicotinamide. The molecule exists in oxidized (NAD+) and reduced (NADH) forms, and the reversible hydride transfer between them underlies many metabolic oxidation-reduction reactions. In cells, NAD+ serves as an electron acceptor in pathways such as glycolysis, the citric acid cycle, and oxidative phosphorylation. Its concentration and redox ratio vary by compartment, tissue, and metabolic state.
Beyond redox chemistry, NAD+ is consumed as a substrate by enzymes that transfer ADP-ribose or remove acetyl groups. Sirtuins use NAD+ in deacylation reactions, poly(ADP-ribose) polymerases use it in DNA damage responses, and CD38 hydrolases convert it to signaling metabolites. Because these enzymes compete for the same pool, changes in NAD+ availability can influence multiple cellular processes. The relative contribution of each consumption route differs by cell type and condition, and precise quantitative links remain an active area of study.
Research on NAD+ spans biochemistry, aging biology, and metabolism. Studies often examine how NAD+ levels change with age, diet, exercise, or disease states, and whether precursor supplementation alters those levels. Findings in animal models do not automatically translate to humans, and measurement methods vary across studies. Questions about tissue-specific effects, long-term consequences, and causal relationships remain open. NAD+ itself is not established as a single therapeutic agent with a broad clinical role.
Beyond redox chemistry, NAD+ acts as a substrate for several enzyme families. ADP-ribosyltransferases, sirtuins, and CD38 ectoenzymes cleave the molecule into nicotinamide and ADP-ribose or related products. These reactions connect NAD+ availability to processes such as DNA repair, chromatin modification, and calcium signaling. Because the coenzyme is used in both electron transfer and signaling, cells maintain separate pools in compartments including the cytosol, mitochondria, and nucleus. The relative sizes and regulation of those pools remain active areas of study.
Cells produce NAD+ through several biosynthetic routes. The salvage pathway recycles nicotinamide, while the Preiss-Handler pathway uses nicotinic acid, and a de novo route can start from tryptophan in some organisms. In mammals, the salvage pathway is generally considered the main source under ordinary conditions. Tissue concentrations vary widely by cell type and compartment, and measured declines with age have been reported in some studies. Whether such changes drive aging or mainly accompany it remains an open question.
Nicotinamide adenine dinucleotide, commonly abbreviated NAD+, is a coenzyme present in all living cells. The molecule consists of two nucleotides linked by phosphate groups, with adenine and a nicotinamide ring as its principal features. In its oxidized form, the nicotinamide ring can accept a hydride ion, becoming NADH. This reversible conversion places NAD+ at the center of many electron-transfer reactions. Its role as a redox carrier is well established across bacteria, plants, fungi, and animals.
=== Category:EC 1.8 (act on a sulfur group of donors) === Category:EC 1.8.1 (with NAD+ or NADP+ as acceptor) Glutathione reductase EC 1.8.1.7 Thioredoxin reductase EC 1.8.1.9 Category:EC 1.8.2 (with a cytochrome as acceptor) Category:EC 1.8.3 (with oxygen as acceptor) Sulfite oxidase EC 1.8.3.1 Category:EC 1.8.4 (with a disulfide as acceptor) Category:EC 1.8.5 (with a quinone or similar compound as acceptor) Category:EC 1.8.6 deleted, included in EC 2.5.1.18 Category:EC 1.8.7 (with an iron–sulfur protein as acceptor) Category:EC 1.8.98 (with other, known, acceptors) Category:EC 1.8.99 (with other acceptors)
Albersheim P, Killias U (1962). "Studies relating to the purification and properties of pectin transeliminase". Arch. Biochem. Biophys. 97 (1): 107–15. doi:10.1016/0003-9861(62)90050-4. PMID 13860094. Edstrom RD, Phaff HJ (1964). "Purification and Certain Properties of Pectin trans-Eliminase from Aspergillus fonsecaeus". J. Biol. Chem. 239 (8): 2403–8. doi:10.1016/S0021-9258(18)93866-4. PMID 14235514. Edstrom RD, Phaff HJ (1964). "Eliminative Cleavage of Pectin and of Oligogalacturonide Methyl Esters by Pectin trans-Eliminase". J. Biol. Chem. 239 (8): 2409–15. doi:10.1016/S0021-9258(18)93867-6. PMID 14235515. Nagel CW, Vaughn RH (1961). "The degradation of oligogalacturonides by the polygalacturonase of Bacillus polymyxa". Arch. Biochem. Biophys. 94 (2): 328–32. doi:10.1016/0003-9861(61)90047-9. PMID 13727438. Nasuno S, Starr MP (1967). "Polygalacturonic acid trans-eliminase of Xanthomonas campestris". Biochem. J. 104 (1): 178–85. doi:10.1042/bj1040178. PMC 1270559. PMID 6035509. Pickersgill R, Jenkins J (1997). "Two crystal structures of pectin lyase A from Aspergillus reveal a pH-driven conformational change and striking divergence in the substrate-binding clefts of pectin and pectate lyases". Structure. 5 (5): 677–89. doi:10.1016/S0969-2126(97)00222-0. PMID 9195887.
=== Patent disputes === The PCR technique was patented by Kary Mullis and assigned to Cetus Corporation, where Mullis worked when he invented the technique in 1983. The Taq polymerase enzyme was also covered by patents. There have been several lawsuits related to the technique brought by DuPont. The Swiss pharmaceutical company Hoffmann-La Roche purchased the rights to the patents in 1992. The last of the commercial PCR patents expired in 2017. A related patent battle over the Taq polymerase enzyme is still ongoing in several jurisdictions around the world between Roche and Promega. The legal arguments have extended beyond the lives of the original PCR and Taq polymerase patents, which expired on 28 March 2005.
The institutions at lower levels were overseen and at times supplanted by primary party organizations. However, in practice the degree of control the party was able to exercise over the state bureaucracy, particularly after the death of Stalin, was far from total, with the bureaucracy pursuing different interests that were at times in conflict with the party, nor was the party itself monolithic from top to bottom, although factions were officially banned.
Sources: en.wikipedia.org
The three substrates of this enzyme are (S)-1-pyrroline-5-carboxylic acid, reduced nicotinamide adenine dinucleotide (NADH), and a proton. Its products are L-proline and oxidised (NAD+). Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is L-proline:NAD(P)+ 5-oxidoreductase. Other names in common use include proline oxidase, L-proline oxidase, 1-pyrroline-5-carboxylate reductase, NADPH-L-Delta1-pyrroline carboxylic acid reductase, and L-proline-NAD(P)+ 5-oxidoreductase. This enzyme participates in arginine and proline metabolism.
== Functions == Some fusion proteins combine whole peptides and therefore contain all functional domains of the original proteins. However, other fusion proteins, especially those that occur naturally, combine only portions of coding sequences and therefore do not maintain the original functions of the parental genes that formed them. Many whole gene fusions are fully functional and can still act to replace the original peptides. Some, however, experience interactions between the two proteins that can modify their functions. Beyond these effects, some gene fusions may cause regulatory changes that alter when and where these genes act. For partial gene fusions, the shuffling of different active sites and binding domains have the potential to result in new proteins with novel functions.
Electron ionization was first described in 1918 by Canadian-American Physicist Arthur J. Dempster in the article of "A new method of positive ray analysis." It was the first modern mass spectrometer and used positive rays to determine the ratio of the mass to charge of various constituents. In this method, the ion source used an electron beam directed at a solid surface. The anode was made cylindrical in shape using the metal which was to be studied. Subsequently, it was heated by a concentric coil and then was bombarded with electrons. Using this method, the two isotopes of lithium and three isotopes of magnesium, with their atomic weights and relative proportions, were able to be determined. Since then this technique has been used with further modifications and developments. The use of a focused monoenergetic beam of electrons for ionization of gas phase atoms and molecules was developed by Bleakney in 1929.
Sources: en.wikipedia.org
== Structure == Osteocytes have a stellate shape, approximately 7 micrometers deep and wide by 15 micrometers in length. The cell body varies in size from 5–20 micrometers in diameter and contain 40–60 cell processes per cell, with a cell to cell distance between 20–30 micrometers. A mature osteocyte contains a single nucleus that is located toward the vascular side and has one or two nucleoli and a membrane. The cell also exhibits a reduced size endoplasmic reticulum, Golgi apparatus and mitochondria, and cell processes that radiate largely towards the bone surfaces in circumferential lamellae, or towards a haversian canal and outer cement line typical of osteons in concentric lamellar bone. Osteocytes form an extensive lacunocanalicular network within the mineralized collagen type I matrix, with cell bodies residing within lacunae, and cell/dendritic processes within channels called canaliculi.
=== Primary glaucoma and its variants === Primary glaucoma (H40.1-H40.2) includes primary open-angle glaucoma (chronic open-angle, chronic simple, glaucoma simplex), which can be high-tension or low-tension, and primary angle closure glaucoma (primary closed-angle, narrow-angle, pupil-block, acute congestive), which can manifest as acute, chronic, intermittent, or superimposed on chronic open-angle closure glaucoma (also called "combined mechanism" glaucoma). Other variants of primary glaucoma include:
Sulfur compounds are chemical compounds formed with the element sulfur (S). Common oxidation states of sulfur range from −2 to +6. Sulfur forms stable compounds with all elements except the noble gases.
== History == The drug was first discovered by scientists including Axel Ullrich and H. Michael Shepard at Genentech, Inc. in South San Francisco, CA. Earlier discovery about the neu oncogene by Robert Weinberg's lab and the monoclonal antibody recognizing the oncogenic receptor by Mark Greene's lab also contributed to the establishment of HER2 targeted therapies. Dr. Dennis Slamon subsequently worked on trastuzumab's development. A book about Dr. Slamon's work was made into a television film called Living Proof, that premiered in 2008. Genentech developed trastuzumab jointly with UCLA, beginning the first clinical trial with 15 women in 1992. By 1996, clinical trials had expanded to over 900 women, but due to pressure from advocates based on early success, Genentech worked with the FDA to begin a lottery system allowing 100 women each quarter access to the medication outside the trials. Herceptin was Fast-tracked by the FDA and gained approval in September 1998. Biocon Ltd and its partner Mylan obtained regulatory approval to sell a biosimilar in 2014, but Roche contested the legality of the approval; that litigation ended in 2016, and Biocon and Mylan each introduced their own branded biosimilars.
Sources: en.wikipedia.org
Many enzymes consume or produce NAD+ within seconds after a sample is collected. Quenching stops those reactions and helps preserve the ratio between oxidized and reduced forms. The exact quenching method depends on the tissue or cell type and the analytes of interest.
NAD+ is present in blood cells, but plasma measurements are complicated by release from cells during processing. Careful collection and immediate separation of cellular components are required. Researchers often prefer specific cell or tissue samples to answer questions about NAD+ pools.
Solid NAD+ is dissolved in suitable aqueous buffer, often near neutral pH, and kept cold. Solutions are typically aliquoted to avoid repeated freeze-thaw cycles. Protection from light and microbial contamination supports stability during storage.
Researchers often use enzymatic cycling assays, liquid chromatography, or mass spectrometry. The choice depends on sample size, sensitivity needs, and available equipment. Because NAD+ can degrade quickly, rapid extraction and careful handling are important.